Prevalence of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation

Clinical Therapeutics

Volumn 18, Issue SUPPL. B, 1996, Pages 59-70

  Scheiblauer, Heiner ^a   Nübling, Micha ^a   Willkommen, Hannelore ^a   Löwer, Johannes ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DERIVATIVE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; VIRUS RNA;

ANIMAL CELL; BOVINE DIARRHEA VIRUS; COLD; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MANUFACTURE; FRACTIONATION; HEPATITIS C VIRUS; NONHUMAN; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; SCREENING; TECHNIQUE; VIRUS INACTIVATION;

EID: 0029860770     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80196-2     Document Type: Conference Paper

References (33)

1. Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362.
2. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. NEJM. 1992;327: 369-373.
3. Huang YY, Yang SS, Wu CH, et al. Impact of screening blood donors for hepatitis C antibody on posttransfusion hepatitis: A prospective study with a second-generation anti-hepatitis C virus assay. Transfusion. 1994;34:661-665.
4. Wang YJ, Lee SD, Hwang SJ, et al. Incidence of post-transfusion hepatitis before and after screening for hepatitis C virus antibody. Vox Sang. 1994;67:187-190.
5. Habibi B, Garretta M. Screening for hepatitis C virus antibody in plasma for fractionation. Lancet. 1990;335:855-856.
6. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet. 1983; 2:974-975.
7. Ochs HD, Fisher SH, Virant FS, et al. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet. 1985;1:404-405.
8. Weiland O, Mattson L, Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986;1:976-977.
9. Björkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988;84:107-111.
10. Williams PE, Yap PL, Gillon J, et al. Non-A, non-B hepatitis transmission by intravenous immunoglobulin. Lancet. 1988;2: 501. Letter.
11. Dürkop J, Roggendorf M, Wiese M, et al. Antikörper gegen das Hepatitis C-Virus (anti-HCV) bei akuter und chronischer parenteral übertragbarer Hepatitis Non-A, Non-B (HNANB[P]). Z Klin Med. 1990; 45:1833-1835.
12. Power JP, Lawlor E, Davidson F, et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet. 1995;345:1211-1213.
13. Yap PL, McOmish F, Webster AD, et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol. 1994; 21:455-460.
14. Finlayson JS, Tankersley DL. Anti-HCV screening and plasma fractionation: The case against. Lancet. 1990;335:1274-1275.
15. Nübling CM, von Wangenheim G, Staszewski S, Löwer J. Hepatitis C virus antibody prevalence among human immunodeficiency virus-1-infected individuals: Analysis with different test systems. J Med Virol. 1994;44:49-53.
16. Cohn FJ, Strong LE, Hughes WL Jr, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459-475.
17. Oncley JL, Melin M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen, and beta-1-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949; 71:541-550.
18. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol. 1931;162:480-483.
19. Yu MW, Mason BL, Guo ZP, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet. 1995; 345:1173-1174.
20. Yu MW, Mason BL, Guo ZP, Tankersley DL. Safety of intravenous immunoglobulin with regard to hepatitis C virus. Clin Ther. 1996;18(Suppl B):71-72.
21. Miller RH, Purcell RH. Hepatitis C virus shares amino acid similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci USA. 1990;87:2057-2061.
22. Bradley D, McCaustland K, Krawczynski K, et al. Hepatitis C virus: Buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol. 1991;34:206-208.
23. Brown EA, Zhang H, Ping L-H, Lemon SM. Secondary structure of the 5′ non-translated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res. 1992;20:5041-5045.
24. Gomperts ED. Gammagard® and reported hepatitis C virus episodes. Clin Ther. 1996;18(Suppl B):3-8.
25. Damen M, Cuypers HTM, Zaaijer HL, et al. International collaborative study on the Eurohep HCV-RNA reference panel. J Virol Methods. In press.
26. Simmonds P. Virology of hepatitis C virus. Clin Ther. 1996;18(Suppl B):9-36.
27. Thomssen R, Bonk S, Propfe C, et al. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol. 1992;181:293-300.
28. Kistler P, Nitschmann H. Large scale production of human plasma fractions. Vox Sang. 1962;7:414-424.
29. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion. 1992;32:824-828.
30. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Biologicals. 1991;19:247-251.
31. Dichtelmüller H, Rudnick D, Breuer B, Gänshirt KH. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone. Biologicals. 1993;21: 259-268.
32. Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J Virol. 1993;67: 1953-1958.
33. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol. 1993;182:329-334.